This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-06-1199v1 66/23/11314    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Puttini, M. Articles by Gambacorti-Passerini, C. Search for Related Content PubMed PubMed Citation Articles by Puttini, M. Articles by Gambacorti-Passerini, C.

In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl⁺ Neoplastic Cells

¹ Department of Clinical Medicine, S. Gerardo Hospital-University of Milano-Bicocca, Monza, Italy; ² Department of Oncology, Wyeth Research, Pearl River, New York; ³ Department of Experimental Oncology, National Cancer Institute, Milan, Italy; ⁴ Department of Biological Chemistry and Centro Interdipartimentale di Ricerca e Servizi per le Biotecnologie Innovative, National Research Centre, Institute of Neuroscience, University of Padova, Padova, Italy; ⁵ Pharmaceutical Biochemistry Group, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland; and ⁶ Department of Oncology, McGill University, Jewish General Hospital, Montreal, Quebec, Canada

Requests for reprints: Carlo Gambacorti-Passerini, Internal Medicine, Department of Clinical Medicine and Prevention and Biotechnologies, University of Milano-Bicocca, via Cadore 48, 20052 Monza, Italy. Phone: 39-039-233-3539; Fax: 39-039-233-3539; E-mail: carlo.gambacorti{at}unimib.it.

Resistance to imatinib represents an important scientific and clinical issue in chronic myelogenous leukemia. In the present study, the effects of the novel inhibitor SKI-606 on various models of resistance to imatinib were studied. SKI-606 proved to be an active inhibitor of Bcr-Abl in several chronic myelogenous leukemia cell lines and transfectants, with IC₅₀ values in the low nanomolar range, 1 to 2 logs lower than those obtained with imatinib. Cells expressing activated forms of KIT or platelet-derived growth factor receptor (PDGFR), two additional targets of imatinib, were unaffected by SKI-606, whereas activity was found against PIM2. SKI-606 retained activity in cells where resistance to imatinib was caused by BCR-ABL gene amplification and in three of four Bcr-Abl point mutants tested. In vivo experiments confirmed SKI-606 activity in models where resistance was not caused by mutations as well as in cells carrying the Y253F, E255K, and D276G mutations. Modeling considerations attribute the superior activity of SKI-606 to its ability to bind a conformation of Bcr-Abl different from imatinib. (Cancer Res 2006; 66(23): 11314-22)

This article has been cited by other articles:

				C. S. Tam, H. Kantarjian, G. Garcia-Manero, G. Borthakur, S. O'Brien, F. Ravandi, J. Shan, and J. Cortes Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia Blood, August 1, 2008; 112(3): 516 - 518. [Abstract] [Full Text] [PDF]

				M. Puttini, S. Redaelli, L. Moretti, S. Brussolo, R. H Gunby, L. Mologni, E. Marchesi, L. Cleris, A. Donella-Deana, P. Drueckes, et al. Characterization of compound 584, an Abl kinase inhibitor with lasting effects Haematologica, May 1, 2008; 93(5): 653 - 661. [Abstract] [Full Text] [PDF]

				A. Gontarewicz, S. Balabanov, G. Keller, R. Colombo, A. Graziano, E. Pesenti, D. Benten, C. Bokemeyer, W. Fiedler, J. Moll, et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I Blood, April 15, 2008; 111(8): 4355 - 4364. [Abstract] [Full Text] [PDF]

				J. M. Goldman How I treat chronic myeloid leukemia in the imatinib era Blood, October 15, 2007; 110(8): 2828 - 2837. [Abstract] [Full Text] [PDF]

				A. Quintas-Cardama, H. Kantarjian, S. O'Brien, G. Borthakur, J. Bruzzi, R. Munden, and J. Cortes Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure J. Clin. Oncol., September 1, 2007; 25(25): 3908 - 3914. [Abstract] [Full Text] [PDF]

				M. Modugno, E. Casale, C. Soncini, P. Rosettani, R. Colombo, R. Lupi, L. Rusconi, D. Fancelli, P. Carpinelli, A. D. Cameron, et al. Crystal Structure of the T315I Abl Mutant in Complex with the Aurora Kinases Inhibitor PHA-739358 Cancer Res., September 1, 2007; 67(17): 7987 - 7990. [Abstract] [Full Text] [PDF]

				N. P. Shah Medical Management of CML Hematology, January 1, 2007; 2007(1): 371 - 375. [Abstract] [Full Text] [PDF]